Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yellow catfish protein hydrolysate is a bioactive peptide mixture produced through the enzymatic digestion of proteins from the yellow catfish (*Pelteobagrus fulvidraco*). Research in animal models of obesity has demonstrated that the hydrolysate exerts anti-obesity effects by inhibiting adipogenesis and promoting lipid metabolism. Its mechanism of action involves the downregulation of key adipogenic transcription factors, including Peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT/enhancer-binding protein alpha (C/EBPα), and Sterol regulatory element-binding protein 1 (SREBP-1c), alongside the activation of the AMP-activated protein kinase (AMPK) signaling pathway. It is primarily investigated as a functional food ingredient or nutraceutical for the management of metabolic disorders such as obesity and hyperlipidemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yellow catfish protein hydrolysate.